{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:23:34Z","timestamp":1760189014546},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.ygyno.2008.07.049","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T09:16:28Z","timestamp":1222852588000},"page":"455-460","source":"Crossref","is-referenced-by-count":43,"title":["A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study"],"prefix":"10.1016","volume":"111","author":[{"given":"Paul","family":"Sabbatini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2008.07.049_bib1","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2008.07.049_bib3","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"18","author":"McGuire","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib5","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinik","year":"1997","journal-title":"Journal of Clinical Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.gco.0000192996.20040.24","article-title":"Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients","volume":"18","author":"Kayl","year":"2006","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0169-409X(02)00045-5","article-title":"Poly(l-glutamic acid)-anticancer drug conjugates","volume":"54","author":"Li","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ygyno.2008.07.049_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1586\/14737140.7.4.415","article-title":"Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer","volume":"7","author":"Bonomi","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ygyno.2008.07.049_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00001813-200503000-00003","article-title":"Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane","volume":"16","author":"Singer","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ygyno.2008.07.049_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-006-0296-4","article-title":"In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases","volume":"59","author":"Shaffer","year":"2007","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s002800000168","article-title":"Biodistribution of paclitaxel and poly(l-glutamic acid)\u2013paclitaxel conjugate in mice with ovarian OCa-1 tumor","volume":"46","author":"Li","year":"2000","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1006\/gyno.2001.6331","article-title":"Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies","volume":"82","author":"Robinson","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2008.07.049_bib14","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Ng TH. Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Statist. Med."},{"key":"10.1016\/j.ygyno.2008.07.049_bib15","series-title":"Modelling survival data in medical research","author":"Collett","year":"2003"},{"key":"10.1016\/j.ygyno.2008.07.049_bib16","unstructured":"Arbuck SG, Ivy SP, Setser A, et al., The revised common toxicity criteria: version 2.0. CTEP Website. http:\/\/ctep.info.nih.gov."},{"key":"10.1016\/j.ygyno.2008.07.049_bib17","series-title":"Analysis of ordinal categorical data","author":"Agresti","year":"1984"},{"key":"10.1016\/j.ygyno.2008.07.049_bib18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/gyno.2000.5958","article-title":"Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy","volume":"79","author":"Zanotti","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib20","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1993.11.12.2405","article-title":"Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103","volume":"11","author":"Trimble","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1200\/JCO.1996.14.3.796","article-title":"Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer","volume":"14","author":"Markman","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 3","key":"10.1016\/j.ygyno.2008.07.049_bib22","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/sj.bjc.6601496","article-title":"The taxanes: toxicity and quality of life considerations in advanced ovarian cancer","volume":"89","author":"Guastalla","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2008.07.049_bib23","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80\u00a0mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib25","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/JCO.2004.12.043","article-title":"Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"22","author":"Sabbatini","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.07.049_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00491763","article-title":"Renal cathepsin-B activities in rats after castration and treatment with sex hormones","volume":"85","author":"Kugler","year":"1986","journal-title":"Histochemistry"},{"key":"10.1016\/j.ygyno.2008.07.049_bib27","unstructured":"Allievi C, Strepponi I, Bastrup U, Piazzoni S, Tavazzi R, Pisano G, et al., Biodistribution of paclitaxel poliglumex (PPX) in lung: Analysis of gender related alterations in a pre-clinical model. PROC ASCO 25:abs 17003, 2006."},{"issue":"4","key":"10.1016\/j.ygyno.2008.07.049_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10637-007-9034-y","article-title":"Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions","volume":"25","author":"Lin","year":"2007","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ygyno.2008.07.049_bib29","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel\u2013carboplatin versus paclitaxel\u2013carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2008.07.049_bib30","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808005489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808005489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T10:23:44Z","timestamp":1557829424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825808005489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0090825808005489"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.07.049","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}